Abstract
The success of cancer gene therapy is likely to require the targeting of multiple antitumor mechanisms. In this study we demonstrate that infection of Lewis rats bearing pancreatic tumors with the Adenoassociated Virus type 2 (AAV-2) induces a systemic anti-tumor response and protects these animals from a subsequent tumor rechallenge.
AAV-2 is a small single stranded parvovirus with tumorsuppressive properties. DSL6A pancreatic tumor cells were inoculated subcutaneously and after 6 weeks AAV-2 infection with 108 virus particles was performed intratumorly (i. t.) or intra-peritoneally (i. p.) twice a week for 1 month. In this syngeneic tumor model the well established tumor (average size of 8 × 8 mm) was completely resected (Ro) 10 weeks after tumor cell inoculation. Six weeks later no local tumor recurrence was detected and tumor rechallenge experiment (106 DSL6A cells) on a different site was done.
Within the next 8 weeks 11 of 12 (92%) untreated Lewis rats developed again a solid pancreatic tumor. In contrast, in case of TNF-α AAV-2-infected animals only 3 of 12 (25%) showed tumor growth. Analysis of cytokine profile demonstrated no significant changes of IL1β, IL4, IL6, INFγ and TNF-α, but the systemic cytokine level of IL10 and MCP-1 were significantly elevated in AAV-2 infected rats. 51Cr release assay revealed an enhanced anti-tumoral activity mostly provided by natural killer cells in AAV-2 infected animals. In line with these results further experiments showed that AAV-2 infection intratumorly was strongly associated with an enhanced infiltration of monocytes, macrophages, natural killer cells and CD8+ cytotoxic T lymphocytes.
These results suggest that AAV-2 vaccination may stimulate the immune system and activate effector cells to protect Lewis rats against tumor cell challenge.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Literatur
Eisold S, Dihlmann S, Linnebacher M, Ryschich E, Aulmann M, Schmidt J, Schlehofer JR, Ridder R, von Knebel Doeberitz M (2002) Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2. Int J Cancer 10; 100(5):606–614
Haack K, Linnebacher M, Eisold S, Zoller M, von Knebel Doeberitz M, Gebert J (2000) Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase gene. J Cancer Gene Therapy, Vol 7, No 10:1357–1364
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Medizin Verlag Heidelberg
About this paper
Cite this paper
Eisold, S., Klar, E., Dähmel, W., von Knebel-Doeberitz, M., Linnebacher, M. (2005). Die Applikation von Adeno-assoziierten Viren Typ 2 (AAV-2) führt zur Tumorprotektion in einem syngenen Rattenmodell des Pankreaskarzinoms. In: Rothmund, M., Jauch, KW., Bauer, H. (eds) Chirurgisches Forum 2005. Deutsche Gesellschaft für Chirurgie, vol 34. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26560-0_44
Download citation
DOI: https://doi.org/10.1007/3-540-26560-0_44
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-24888-0
Online ISBN: 978-3-540-26560-3
eBook Packages: Medicine (German Language)